Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

Background Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR‐1 and ‐2), respectively. This open‐label, randomized phase II study evaluated their efficacy and safety in combination with capecitabine (CAP) in patients with previously treated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2017-03, Vol.22 (3), p.245-254
Hauptverfasser:	Vahdat, Linda T., Layman, Rachel, Yardley, Denise A., Gradishar, William, Salkeni, Mohamad A., Joy, Anil Abraham, Garcia, Agustin A., Ward, Patrick, Khatcheressian, James, Sparano, Joseph, Rodriguez, Gladys, Tang, Shande, Gao, Ling, Dalal, Rita P., Kauh, John, Miller, Kathy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast Cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Capecitabine Capecitabine - administration & dosage Capecitabine - adverse effects Disease-Free Survival Drug resistance Drug Resistance, Neoplasm - genetics Drug-Related Side Effects and Adverse Reactions - pathology Female Humans Metastasis Middle Aged Monoclonal antibodies Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - genetics Neovascularization, Pathologic - pathology Ramucirumab Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors Vascular Endothelial Growth Factor Receptor-1 - genetics Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors Vascular Endothelial Growth Factor Receptor-2 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!